Search results for " glycoprotein"

showing 10 items of 430 documents

The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38

2018

The relationship between bone and immune cells is well established both in physiological and pathological conditions. Multiple myeloma (MM) is a plasma cell malignancy characterized by an increase of number and activity of osteoclasts (OCLs) and a decrease of osteoblasts (OBs). These events are responsible for bone lesions of MM patients. OCLs support MM cells survival in vitro and in vivo. Recently, the possible role of OCLs as immunosuppressive cells in the MM BM microenvironment has been underlined. OCLs protect MM cells against T cell-mediated cytotoxicity through the expression of several molecules including programmed death-ligand (PD-L) 1, galectin (Gal) 9, CD200, and indoleamine-2,3…

0301 basic medicinemedicine.drug_classT-LymphocytesT cellImmunologyOsteoclastsPlasma cellCD38Monoclonal antibodyImmunomodulation03 medical and health sciencesImmune systemOsteogenesisOsteoclastTumor MicroenvironmentmedicineAnimalsHumansImmunology and AllergyGalectinMembrane GlycoproteinsChemistryAntibodies MonoclonalOsteoblastADP-ribosyl Cyclase 1030104 developmental biologymedicine.anatomical_structureCancer researchMultiple MyelomaImmunology Letters
researchProduct

Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter …

2020

ABSTRACT Resection of colorectal liver metastases (CRLM) is a potential curative treatment for patients with metastatic colorectal cancer (mCRC) with liver-limited disease (LLD). Although long-term survival improved considerably within the last decades, high recurrence rates of 50-75% after resection remain a major challenge.Tecemotide (L-BLP25) is an antigen-specific cancer vaccine inducing immunity against mucin-1 (MUC1). The LICC trial aimed to improve survival in patients with mCRC after R0/R1 resection of CRLM. LICC was a binational, randomized, double-blind, placebo-controlled, multicenter phase 2 study including patients with R0/R1 resected CRLM without evidence of metastatic disease…

0301 basic medicinemedicine.medical_specialtyLung Neoplasmsmucin-1 (muc1)Colorectal cancermedicine.medical_treatmentImmunologyMedizinPlaceboCancer VaccinesGastroenterologyResectionDouble blind03 medical and health sciences0302 clinical medicineCarcinoma Non-Small-Cell LungGermanyInternal medicinemedicineHumansImmunology and AllergyRC254-282Original ResearchMembrane Glycoproteinsresection of colorectal liver metastasesbusiness.industryLiver NeoplasmsVaccinationNeoplasms. Tumors. Oncology. Including cancer and carcinogenscolorectal neoplasmsRC581-607medicine.diseasedigestive system diseasesVaccination030104 developmental biologyOncologyCurative treatment030220 oncology & carcinogenesistecemotide (l-blp25)TecemotideNeoplasm Recurrence LocalImmunologic diseases. AllergybusinessAdjuvantResearch Articleliver-limited diseaseOncoImmunology
researchProduct

Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy

2020

For the diagnosis of anti-MAG polyneuropathy the commercial ELISA manufacturer currently recommends a cut-off of 1000 Bühlmann Titer Units (BTU). We analyzed sera from 80 anti-MAG neuropathy patients and 383 controls (with other neuropathies or healthy controls) to assess the ELISA sensitivity and specificity at different thresholds. A better combination of sensitivity/specificity was found at a threshold >1500 BTU than at >1000 BTU. The best value of specificity was obtained at threshold >7000 BTU. There was a diagnostic grey area between 1500 and 7000 BTU in which the clinical phenotypes as well as electrophysiological studies need to be carefully assessed particularly to differe…

0301 basic medicinemedicine.medical_specialtyanti-MAG polyneuropathy; chronic inflammatory demyelinating polyradiculoneuropathy; ELISA; sensitivity; specificity; autoantibodies; case-control studies; enzyme-linked immunosorbent assay; humans; myelin-associated glycoprotein; polyneuropathies; retrospective studiesImmunologyAnti-MAG polyneuropathyEnzyme-Linked Immunosorbent AssaySettore MED/26GastroenterologyPolyneuropathies03 medical and health sciencesSensitivity0302 clinical medicineInternal medicinemedicineHumansImmunology and AllergyIn patientAutoantibodiesRetrospective Studieschronic inflammatory demyelinating polyradiculoneuropathyAnti-MAG polyneuropathy chronic inflammatory demyelinating polyradiculoneuropathybiologybusiness.industryAnti magAnti-MAG polyneuropathy chronic inflammatory demyelinating polyradiculoneuropathy; ELISA; Sensitivity; Specificitymedicine.diseaseAutoantibodieMyelin-Associated GlycoproteinTiter030104 developmental biologyPolyneuropathienervous systemNeurologyCase-Control StudiesElisa testSpecificitybiology.proteinELISANeurology (clinical)AntibodyCase-Control StudiebusinessSensitivity (electronics)Polyneuropathy030217 neurology & neurosurgeryHumanJournal of Neuroimmunology
researchProduct

Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)?

2020

Abstract Although some demographic, clinical and environmental factors have been associated with a higher risk of developing coronavirus disease 2019 (COVID-19) and progressing towards severe disease, altogether these variables do not completely account for the different clinical presentations observed in patients with comparable baseline risk, whereby some subjects may remain totally asymptomatic, whilst others develop a very aggressive illness. Some predisposing genetic backgrounds can hence potentially explain the broad inter-individual variation of disease susceptibility and/or severity. It has been now clearly established that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2…

0301 basic medicinereceptorClinical BiochemistryPopulationPneumonia ViralAdipose tissueInflammationPeptidyl-Dipeptidase AAsymptomaticViruspolymorphism03 medical and health sciencesBetacoronavirus0302 clinical medicineProtein DomainsFibrosismedicineHumans030212 general & internal medicineeducationGenePandemicseducation.field_of_studyPolymorphism Geneticbusiness.industrySARS-CoV-2Biochemistry (medical)COVID-19General Medicineangiotensinmedicine.diseaseenzyme030104 developmental biologyCOVID-19 angiotensin enzyme polymorphism receptorImmunologyAngiotensin-converting enzyme 2Spike Glycoprotein CoronavirusReceptors VirusAngiotensin-Converting Enzyme 2medicine.symptombusinessCoronavirus InfectionsProtein Binding
researchProduct

Identification and expansion of human colon-cancer-initiating cells

2007

Colon carcinoma is the second most common cause of death from cancer. The isolation and characterization of tumorigenic colon cancer cells may help to devise novel diagnostic and therapeutic procedures. Although there is increasing evidence that a rare population of undifferentiated cells is responsible for tumour formation and maintenance, this has not been explored for colorectal cancer. Here, we show that tumorigenic cells in colon cancer are included in the high-density CD133+ population, which accounts for about 2.5% of the tumour cells. Subcutaneous injection of colon cancer CD133+ cells readily reproduced the original tumour in immunodeficient mice, whereas CD133- cells did not form …

AC133 Antigen; Animals; Antigens CD; Cell Differentiation; Cell Line Tumor; Cell Proliferation; Colonic Neoplasms; Glycoproteins; Humans; Mice; Mice SCID; Neoplasm Transplantation; Neoplastic Stem Cells; Peptides; Phenotype; Transplantation Heterologous; MultidisciplinaryColorectal cancerCellular differentiationPopulationTransplantation HeterologousTumor initiationMice SCIDBiologyColon carcinomasmedicine.disease_causeSCIDCell LineMiceSide populationCancer stem cellAntigens CDSettore MED/04 - PATOLOGIA GENERALECell Line TumormedicineAnimalsHumansAC133 AntigenAntigenseducationCell ProliferationGlycoproteinseducation.field_of_studyTransplantationHeterologousTumorMultidisciplinaryCancerCell Differentiationmedicine.diseaseCDPhenotypeImmunologyColonic NeoplasmsCancer researchNeoplastic Stem CellsCarcinogenesisPeptidesNeoplasm Transplantation
researchProduct

Brothers in arms: proBDNF/BDNF and sAPPα/Aβ-signaling and their common interplay with ADAM10, TrkB, p75NTR, sortilin, and sorLA in the progression of…

2021

Abstract Brain-derived neurotrophic factor (BDNF) is an important modulator for a variety of functions in the central nervous system (CNS). A wealth of evidence, such as reduced mRNA and protein level in the brain, cerebrospinal fluid (CSF), and blood samples of Alzheimer’s disease (AD) patients implicates a crucial role of BDNF in the progression of this disease. Especially, processing and subcellular localization of BDNF and its receptors TrkB and p75 are critical determinants for survival and death in neuronal cells. Similarly, the amyloid precursor protein (APP), a key player in Alzheimer’s disease, and its cleavage fragments sAPPα and Aβ are known for their respective roles in neuropro…

ADAM10Clinical BiochemistryNerve Tissue ProteinsTropomyosin receptor kinase BReceptors Nerve Growth FactorBiochemistryNeuroprotectionADAM10 ProteinAmyloid beta-Protein PrecursorNeurotrophic factorsAlzheimer DiseaseAmyloid precursor proteinHumansReceptor trkBMolecular BiologyLDL-Receptor Related ProteinsAmyloid beta-PeptidesMembrane GlycoproteinsbiologyBrain-Derived Neurotrophic FactorMembrane ProteinsMembrane Transport ProteinsAdaptor Proteins Vesicular Transportnervous systembiology.proteinSignal transductionAmyloid Precursor Protein SecretasesNeuroscienceAmyloid precursor protein secretaseNeurotrophinBiological chemistryReferences
researchProduct

Down-regulation of Endogenous Amyloid Precursor Protein Processing due to Cellular Aging

2005

Processing of amyloid precursor protein (APP) is a well acknowledged central pathogenic mechanism in Alzheimer disease. However, influences of age-associated cellular alterations on the biochemistry of APP processing have not been studied in molecular detail so far. Here, we report that processing of endogenous APP is down-regulated during the aging of normal human fibroblasts (IMR-90). The generation of intracellular APP cleavage products C99, C83, and AICD gradually declines with increasing life span and is accompanied by a reduced secretion of soluble APP (sAPP) and sAPPalpha. Further, the maturation of APP was reduced in senescent cells, which has been shown to be directly mediated by a…

ADAM10NicastrinEndogenyBiochemistryCell LineAmyloid beta-Protein PrecursorMembrane MicrodomainsDownregulation and upregulationEndopeptidasesmental disordersPresenilin-1Amyloid precursor proteinAspartic Acid EndopeptidasesHumansSecretionMolecular BiologyCellular SenescenceMembrane GlycoproteinsbiologyChemistryMembrane ProteinsCell BiologyFibroblastsCholesterolBiochemistrybiology.proteinAmyloid Precursor Protein SecretasesProtein Processing Post-TranslationalAmyloid precursor protein secretaseIntracellularJournal of Biological Chemistry
researchProduct

Glycoprotein and ganglioside changes in human trophoblasts after exposure to pulsed doppler ultrasound

1995

Changes in glycoprotein and ganglioside composition in human trophoblasts (eighth week of gestation) after in vitro exposure to pulsed Doppler ultrasound (pulse duration 1.22 microseconds; repetition frequency 11.1 kHz; center frequency 4 MHz; ISPPA = 175.5 W/cm2; ISPTA = 0.59 W/cm2) were investigated. Evacuated trophoblasts were divided in two halves and insonated for 10 min on top of a 6-cm layer of 5% gelatin in 50-mL tubes (Falcon) at 37 degrees C. One half of each trophoblast was sham insonated and served as an internal control. After insonation trophoblasts were maintained at 37 degrees C for 24 h. Glycoproteins were detected using alpha-D-mannose specific lectins from Galanthus nival…

Acoustics and UltrasonicsImmunoblottingBiophysicsMannoseG(M2) Gangliosidechemistry.chemical_compoundGangliosidesLectinsmedicineG(M3) GangliosideHumansRadiology Nuclear Medicine and imagingGlycoproteinschemistry.chemical_classificationMembrane GlycoproteinsGangliosideGalanthusRadiological and Ultrasound TechnologybiologyChemistryTrophoblastLectinMolecular biologyN-Acetylneuraminic AcidTrophoblastsMolecular WeightMembrane glycoproteinsglycoproteins; gangliosides; lectins; pulsed doppler ultrasoundmedicine.anatomical_structureUltrasonography Doppler PulsedG(M2) GangliosideImmunologySialic Acidsbiology.proteinElectrophoresis Polyacrylamide GelChromatography Thin LayerPlant LectinsGlycoproteinMannoseN-Acetylneuraminic acid
researchProduct

One-Year Outcome of Glycoprotein IIb/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock

2021

Background: We aimed to evaluate the effect of intravenous glycoprotein IIb/IIIa receptor inhibitors (GPIs) on in-hospital survival and mortality during and at the 1-year follow-up in patients undergoing percutaneous coronary intervention (PCI) for myocardial infarction (MI) complicated by cardiogenic shock (CS), who were included in the Polish Registry of Acute Coronary Syndromes (PL-ACS). Methods: From 2003 to 2019, 466,566 MI patients were included in the PL-ACS registry. A total of 10,193 patients with CS received PCI on admission. Among them, GPIs were used in 3934 patients. Results: The patients treated with GPIs were younger, had lower systolic blood pressure on admission, required i…

Acute coronary syndromemedicine.medical_specialtyacute coronary syndrome; cardiogenic shock; glycoprotein IIb/IIIa receptor inhibitors; myocardial infarction; percutaneous coronary interventionmedicine.medical_treatmentArticleacute coronary syndromeInternal medicineAngioplastyRisk of mortalityMedicineMyocardial infarctionAdverse effectbusiness.industryCardiogenic shockcardiogenic shockpercutaneous coronary interventionRPercutaneous coronary interventionGeneral Medicinemedicine.diseaseglycoprotein IIb/IIIa receptor inhibitorsmyocardial infarctionConventional PCICardiologyMedicinebusinessJournal of Clinical Medicine
researchProduct

SARS-CoV-2 antibody persistence after five and twelve months: A cohort study from South-Eastern Norway

2022

Objectives To assess total antibody levels against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS CoV-2) spike protein up to 12 months after Coronavirus Disease (COVID-19) infection in non-vaccinated individuals and the possible predictors of antibody persistence. Methods This is the first part of a prospective multi-centre cohort study. Participants The study included SARS-CoV-2 real-time polymerase chain reaction (RT-PCR) positive and negative participants in South-Eastern Norway from February to December 2020. Possible predictors of SARS-CoV-2 total antibody persistence was assessed. The SARS-CoV-2 total antibody levels against spike protein were measured three to five months aft…

AdultAged 80 and overMaleMultidisciplinaryNorwaySARS-CoV-2COVID-19Middle AgedAntibodies ViralCohort StudiesYoung AdultSpike Glycoprotein CoronavirusHumansFemaleVDP::Medisinske Fag: 700Prospective StudiesAged
researchProduct